Setara Biosciences launched with $90 million in Series A financing, building a rare-disease genetics platform around programs carried forward from Actio Biosciences following Jazz Pharmaceuticals’ acquisition. Setara is led by a team that includes continuity with Actio’s investor base, and it has Jazz as a new shareholder after the acquisition. The company’s lead program, STAR-0871, is a small molecule TRPV4 inhibitor originally developed at Actio as ABS-0871. STAR-0871 is targeted at Charcot-Marie-Tooth disease type 2C, described as a rare inherited neuromuscular disorder driven by gain-of-function TRPV4 mutations, while the company is also exploring potential extension into the overactive bladder market. Setara’s pipeline strategy is framed as “one to many,” leveraging biology observed in a rare 2,500-patient US population to inform treatments for a more prevalent condition. The company’s funding structure, according to the report, emphasizes continuity with existing investors and board involvement. The launch illustrates how acquisition-driven restructuring is creating new venture-backed biotechs with pedigreed targets, aiming to convert translational genetics into broader therapeutic opportunities.